JP2016507570A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507570A5
JP2016507570A5 JP2015557120A JP2015557120A JP2016507570A5 JP 2016507570 A5 JP2016507570 A5 JP 2016507570A5 JP 2015557120 A JP2015557120 A JP 2015557120A JP 2015557120 A JP2015557120 A JP 2015557120A JP 2016507570 A5 JP2016507570 A5 JP 2016507570A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nitrate
heart failure
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507570A (ja
JP6441818B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/015300 external-priority patent/WO2014124256A1/en
Publication of JP2016507570A publication Critical patent/JP2016507570A/ja
Publication of JP2016507570A5 publication Critical patent/JP2016507570A5/ja
Application granted granted Critical
Publication of JP6441818B2 publication Critical patent/JP6441818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557120A 2013-02-07 2014-02-07 心不全の治療法 Active JP6441818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361761863P 2013-02-07 2013-02-07
US61/761,863 2013-02-07
PCT/US2014/015300 WO2014124256A1 (en) 2013-02-07 2014-02-07 Methods of treating heart failure

Publications (3)

Publication Number Publication Date
JP2016507570A JP2016507570A (ja) 2016-03-10
JP2016507570A5 true JP2016507570A5 (enExample) 2017-03-16
JP6441818B2 JP6441818B2 (ja) 2018-12-19

Family

ID=51300154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557120A Active JP6441818B2 (ja) 2013-02-07 2014-02-07 心不全の治療法

Country Status (6)

Country Link
US (1) US20150366901A1 (enExample)
EP (1) EP2953631A4 (enExample)
JP (1) JP6441818B2 (enExample)
CN (1) CN105101977A (enExample)
CA (1) CA2900526C (enExample)
WO (1) WO2014124256A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6531990B2 (ja) * 2013-02-28 2019-06-19 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 心肺血行動態を改善するための無機亜硝酸塩
JP6971495B2 (ja) 2017-03-23 2021-11-24 ミッション ソルト インコーポレイテッド ビートルート含有組成物
US11324748B2 (en) 2017-04-21 2022-05-10 Northeast Ohio Medical University Vasodilators for treatment of heart failure
US10702796B2 (en) * 2017-09-13 2020-07-07 Thermolife International, Llc Enriched root powder products and methods of producing thereof
FI128489B (en) 2018-10-01 2020-06-15 Precordior Oy Equipment for generating information indicating cardiac abnormality

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004884A2 (en) * 2003-07-09 2005-01-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
KR20100014853A (ko) * 2007-02-26 2010-02-11 존 런드버그 아질산염 및 질산염의 신규 용도 및 이를 함유하는 조성물
US20120214818A1 (en) * 2009-09-11 2012-08-23 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) * 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
GB201020811D0 (en) * 2010-12-08 2011-01-19 Solvotrin Innovations Ltd Compounds
US20140112983A1 (en) * 2011-04-14 2014-04-24 Theravasc Inc. Nitrite compositions and uses thereof
JP6531990B2 (ja) * 2013-02-28 2019-06-19 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 心肺血行動態を改善するための無機亜硝酸塩

Similar Documents

Publication Publication Date Title
Wollina Pyoderma gangrenosum–a review
EP4397372A3 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
JP2014533279A5 (enExample)
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
BR112013023724A2 (pt) métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
JP2015505564A5 (enExample)
Armario et al. Therapeutic strategies to improve control of hypertension
JP2016539156A5 (enExample)
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
JP2016512817A5 (enExample)
RU2015139758A (ru) Хиназолины в качестве ингибиторов киназы
WO2009104939A3 (ko) 약제학적 제제
Markel Statins and peripheral arterial disease
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
JP2014513121A5 (enExample)
WO2006053161A8 (en) Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
WO2008033754A3 (en) Xanthine derivatives in methods and compositions for the treatment of vascular depression
FI3298042T3 (fi) B-solujen vähentyminen diagnostisena merkkinä
WO2010007085A3 (en) Use of gcn5 inhibitors in medicine
JP2011500650A5 (enExample)
JP2016525530A5 (enExample)
JP2020512408A5 (enExample)
RU2016145411A (ru) Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости